Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.76 |
| ▸ | EGFR | P00533 | 6/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | KIF5B | P33176 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181034 | 0.87 | RET (1.00) | RETEGFRKDRABCG2MKNK1 | |
| Hydrochloric Acid SCHEMBL6179218 | 0.86 | RET (0.98) | RETEGFRKDRABCG2MKNK1 | |
| SCHEMBL173234 | 0.85 | EGFR (0.60) | RETEGFRKDRABCG2MKNK1 | |
| SCHEMBL15050338 | 0.83 | EGFR (0.71) | RETEGFRKDRABCG2FBP1 | |
| SCHEMBL159107 | 0.81 | EGFR (0.68) | RETEGFRKDRABCG2FBP1 | |
| SCHEMBL8976740 | 0.80 | EGFR (0.69) | RETEGFRABCG2MKNK1HSF1 | |
| SCHEMBL19885300 | 0.80 | EGFR (0.78) | RETEGFRKDRABCG2FBP1 | |
| Hydrochloric Acid SCHEMBL8976301 | 0.79 | EGFR (0.68) | RETEGFRABCG2MKNK1HSF1 | |
| SCHEMBL8976347 | 0.79 | RET (1.00) | RETEGFRKDRABCG2RAF1 | |
| SCHEMBL8088219 | 0.78 | EGFR (0.79) | RETEGFRKDRABCG2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | disclosed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | RET 4064/4885EGFR 4690/4885KDR 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.